Literature DB >> 26845527

Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design.

Nabihah Tayob1, Kim-Anh Do2, Ziding Feng2.   

Abstract

Motivated by an ongoing study to develop a screening test able to identify patients with undiagnosed Sjögren's Syndrome in a symptomatic population, we propose methodology to combine multiple biomarkers and evaluate their performance in a two-stage group sequential design that proceeds as follows: biomarker data is collected from first stage samples; the biomarker panel is built and evaluated; if the panel meets pre-specified performance criteria the study continues to the second stage and the remaining samples are assayed. The design allows us to conserve valuable specimens in the case of inadequate biomarker panel performance. We propose a nonparametric conditional resampling algorithm that uses all the study data to provide unbiased estimates of the biomarker combination rule and the sensitivity of the panel corresponding to specificity of 1-t on the receiver operating characteristic curve (ROC). The Copas and Corbett (2002) correction, for bias resulting from using the same data to derive the combination rule and estimate the ROC, was also evaluated and an improved version was incorporated. An extensive simulation study was conducted to evaluate finite sample performance and propose guidelines for designing studies of this type. The methods were implemented in the National Cancer Institutes Early Detection Network Urinary PCA3 Evaluation Trial.
© 2016, The International Biometric Society.

Entities:  

Keywords:  Biomarker panel; Conditional estimation; Logistic regression; Shrinkage correction; Two-stage design

Mesh:

Substances:

Year:  2016        PMID: 26845527      PMCID: PMC4974170          DOI: 10.1111/biom.12480

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  11 in total

Review 1.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

3.  Preclinical validation of salivary biomarkers for primary Sjögren's syndrome.

Authors:  Shen Hu; Kai Gao; Rodney Pollard; Martha Arellano-Garcia; Hui Zhou; Lei Zhang; David Elashoff; Cees G M Kallenberg; Arjan Vissink; David T Wong
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-08       Impact factor: 4.794

4.  Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility.

Authors:  Margaret Sullivan Pepe; Ziding Feng; Gary Longton; Joseph Koopmeiners
Journal:  Stat Med       Date:  2009-02-28       Impact factor: 2.373

5.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

6.  Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays.

Authors:  Shen Hu; Arjan Vissink; Martha Arellano; Caroline Roozendaal; Hui Zhou; Cees G M Kallenberg; David T Wong
Journal:  Proteomics       Date:  2011-03-17       Impact factor: 3.984

7.  Early termination of a two-stage study to develop and validate a panel of biomarkers.

Authors:  Joseph S Koopmeiners; Rachel Isaksson Vogel
Journal:  Stat Med       Date:  2012-10-02       Impact factor: 2.373

8.  Two-stage biomarker panel study and estimation allowing early termination for futility.

Authors:  Shanshan Zhao; Yingye Zheng; Ross L Prentice; Ziding Feng
Journal:  Biostatistics       Date:  2015-05-11       Impact factor: 5.899

9.  Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Authors:  John T Wei; Ziding Feng; Alan W Partin; Elissa Brown; Ian Thompson; Lori Sokoll; Daniel W Chan; Yair Lotan; Adam S Kibel; J Erik Busby; Mohamed Bidair; Daniel W Lin; Samir S Taneja; Rosalia Viterbo; Aron Y Joon; Jackie Dahlgren; Jacob Kagan; Sudhir Srivastava; Martin G Sanda
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

10.  Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility.

Authors:  Joseph S Koopmeiners; Ziding Feng; Margaret Sullivan Pepe
Journal:  Stat Med       Date:  2012-01-12       Impact factor: 2.373

View more
  3 in total

1.  Pathogenesis-based treatments in primary Sjogren's syndrome using artificial intelligence and advanced machine learning techniques: a systematic literature review.

Authors:  Nathan Foulquier; Pascal Redou; Christophe Le Gal; Bénédicte Rouvière; Jacques-Olivier Pers; Alain Saraux
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

2.  Hybrid design evaluating new biomarkers when there is an existing screening test.

Authors:  Yeonhee Park; Ying Yuan; Jing Ning; Suyu Liu; Ziding Feng
Journal:  Stat Med       Date:  2021-02-04       Impact factor: 2.373

3.  Adding Rigor to Biomarker Evaluations-EDRN Experience.

Authors:  Ziding Feng; Margaret S Pepe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-11-10       Impact factor: 4.254

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.